|Bid||32.50 x 100|
|Ask||33.43 x 100|
|Day's Range||32.83 - 33.10|
|52 Week Range||29.83 - 37.39|
|PE Ratio (TTM)||27.69|
|Dividend & Yield||1.28 (3.87%)|
|1y Target Est||N/A|
AstraZeneca Plc plunged by a record after suffering a setback to its next-generation cancer therapy, hurting Chief Executive Officer Pascal Soriot’s ambition to join the league of the world’s five largest ...
In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.
While Pfizer, Inc.'s (PFE) new drugs like Ibrance and acquisitions like Hospira are likely to drive sales in Q2, genericization of key drugs, pricing pressure and rising competition will hurt sales.